Stephen Stenbeck is appointed as Independent Director of the Company. Mr. Stenbeck retired as a partner of Ernst & Young LLP in 2019, following 36 years of experience serving Fortune 500, midcap, and small cap public company audit clients in the medical device, retail, consumer products, distribution, airline and media and entertainment industries. Mr. Stenbeck currently serves as a board member of Catholic Charities of St. Paul and Minneapolis.
As the Independent Director of Cardiovascular Systems, the total compensation of Stephen Stenbeck at Cardiovascular Systems is $134,170. There are 17 executives at Cardiovascular Systems getting paid more, with Scott Ward having the highest compensation of $4,718,960.
Stephen Stenbeck is 59, he's been the Independent Director of Cardiovascular Systems since 2019. There are 8 older and 17 younger executives at Cardiovascular Systems. The oldest executive at Cardiovascular Systems Inc. is Augustine Lawlor, 64, who is the Independent Director.
Stephen's mailing address filed with the SEC is 1225 OLD HIGHWAY 8 NW, , ST. PAUL, MN, 55112.
Over the last 16 years, insiders at Cardiovascular Systems have traded over $72,999,461 worth of Cardiovascular Systems stock and bought 949,532 units worth $8,687,068 . The most active insiders traders include Capital Management Lp Camber, Augustine Lawlor, and Capital Ltdmaverick Capital.... On average, Cardiovascular Systems executives and independent directors trade stock every 14 days with the average trade being worth of $338,920. The most recent stock trade was executed by Martha Goldberg Aronson on 15 August 2022, trading 2,411 units of CSII stock currently worth $48,220.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
Cardiovascular Systems executives and other stock owners filed with the SEC include: